Allogene Therapeutics enters the back half of July with a striking contradiction at its core: short sellers are piling in aggressively even as the Street maintains a bullish consensus on the company's Phase 3 cema-cel data.
Short interest has jumped 26% in a single week, climbing to 28.2% of the free float — up nearly 47% over the past month. That is a rapid and deliberate build, not noise. The jump is concentrated: shares short leapt from roughly 50 million to 63 million between July 9 and July 10 alone, a single-session step-change that drove the weekly move. What makes this unusual is the borrow market's lack of strain. Cost to borrow has actually fallen 29% this week to just 0.34%, one of its lowest readings in the past 30 days. Availability is ample at roughly 202% of current short interest, down from above 400% a month ago as the build absorbs supply, but still well within normal territory. Short sellers are not paying a premium to press this trade — borrow is plentiful and cheap, which means the position can be carried without meaningful friction. Options traders are not amplifying the bearish signal: the put/call ratio of 0.19 is barely above its 20-day average and sits toward the low end of its 52-week range, suggesting the options market is not pricing elevated downside risk.
The Street remains constructive in aggregate, but the most recent analyst actions — all of which date to April and are now three months stale — offer limited guidance for current positioning. Around the April earnings cycle, JPMorgan upgraded the name to Neutral, while a cluster of buy-side firms including Baird, HC Wainwright, and Jefferies raised their targets into the $9–$12 range. The consensus buy rating with a mean price target near $8.50 implies substantial upside from the current $1.85 close. However, that gap deserves a note of caution: a stock trading near $1.85 against an $8.50 mean target reflects either a dramatic de-rating since April or targets that have not been refreshed since the positive Phase 3 readout. The ORTEX short score has risen to 70.1, its highest level in the available history, ranking ALLO in only the 14th percentile on short score — meaning the data is flagging elevated short-side pressure relative to most names in the universe. Factor scores reinforce the caution: EPS momentum over both 30 and 90 days ranks in the bottom quartile, and the dividend score of 37 reflects the cash-burn profile of a clinical-stage biotech.
Institutional flows show an interesting split worth noting. Frazier Life Sciences added over 16 million shares in the most recently reported period, making it the third-largest holder at 5.4% of shares. BlackRock and State Street both added meaningful positions in the quarter to June. Against that, Patient Square Capital trimmed by 1.5 million shares. Pfizer Venture Investments and TPG Capital each hold around 5–6% stakes with no reported change, suggesting strategic holders are staying put while more active managers are moving in opposite directions. Insider activity is de minimis — a modest award to a founder-director and a handful of small executive sales averaging well below $200,000 in value — providing no directional signal of note.
Earnings are scheduled for August 7. The stock's recent history around results is mixed and volatile: the June 18 event produced a 7% one-day gain, while the May 13 print triggered a 7% drop followed by a 17% decline over five days. The five-day reaction pattern has been the more consequential signal. This week ALLO fell 14%, broadly in line with closely correlated peers — ARCT dropped 16% and LYEL fell 16%, while LRMR bucked the trend with a 9% gain — suggesting sector-wide de-risking rather than stock-specific deterioration. The key tension to watch into August 7 is whether the short build continues to absorb the ample available borrow, and how quickly, if at all, analyst targets are refreshed to reflect the current price level against the Phase 3 data story.
See the live data behind this article on ORTEX.
Open ALLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
